Hematopoietic Cell Transplant and Solid Organ Transplantation: A First Report of the U.S. Experience.
Surgery, Division of Transplant Surgery, University of Pennsylvania, Philadelphia, PA.
Meeting: 2016 American Transplant Congress
Abstract number: 460
Keywords: Bone marrow transplantation, Outcome, Risk factors, Survival
Session Information
Session Name: Concurrent Session: PTLD and Malignancies
Session Type: Concurrent Session
Date: Tuesday, June 14, 2016
Session Time: 2:30pm-4:00pm
Presentation Time: 3:42pm-3:54pm
Location: Room 206
The prevalence of patients who receive both a hematopoetic cell(HCT) and solid organ transplantation(SOT) is rising. There have been no large scale studies of HCT and SOT recipients in the United States describing the natural history of disease, transplant experience, and outcomes. Methods: Data from the Center for International Bone & Marrow Transplant Registry(CIBMTR) and United Network for Organ Sharing(UNOS), were merged for descriptive and comparative analyses of patients who received HCT and SOT from 1985-2010. Results: Eighty-seven patients underwent a SOT: 65 received SOT prior to HCT, while 22 underwent SOT after HCT.
| Baseline Characteristics of Transplant Patients by Initial Transplant Type | HCT n=22 |
SOT n=63 |
| Age at Hematopoetic Cell Transplant(HCT), Mean Years(SD) | 36.4(18.8) | 45.4(18.7) |
| Age at Solid Organ Transplant(SOT), Mean Years(SD) | 38.5(18.8) | 38.6(19.6) |
| Gender | ||
| Male | 14(63.6%) | 44(69.8%) |
| Female | 8(36.4%) | 19(30.2%) |
| HCT Type | ||
| Allogeneic | 13(59.1%) | 32(50.8%) |
| Autologous | 9(40.9%) | 31(49.2%) |
| HCT Donor Type | ||
| Autologous | 9(40.9%) | 31(49.2%) |
| HLA-Matched Siblings | 2(9.1%) | 11(17.4%) |
| Unrelated | 11(50.0%) | 19(30.2%) |
| Other Relative | 0(0.0%) | 2(3.2%) |
| SOT Type | ||
| Kidney | 14(63.6%) | 30(47.6%) |
| Liver | 3(13.7%) | 20(31.8%) |
| Thoracic (Heart or Lung) | 5(22.7%) | 13(20.6%) |
| SOT Donor Type | ||
| Deceased | 9(40.9%) | 43(68.3%) |
| Living | 13(59.1%) | 20(31.7%) |
| ** Data not shown for patients undergoing pancreas transplant (n=1) and simultaneous kidney-pancreas transplant (n=1) |
Median time between transplant experiences was 39(IQR16-114) months. Patients with initial HCT received SOT earlier[median 26(16-40) months] versus those with initial SOT[median 49(15-126) months]. Living donation for SOT was higher among patients who had initial HCT(59.1%) versus those with SOT first(31.7%). Graft-versus-host disease was not an indication for HCT after SOT. There was no difference in SOT graft survival between patients with initial allogeneic versus autologous HCT(p=0.82). Three-year SOT graft survival for patients with initial HCT(80.6%) was similar to those with initial SOT(82.3%). Conclusions: This is the first review of the national experience of patients with SOT and HCT. Early solid organ outcomes for patients with initial HCT are not inferior to those who require HCT after SOT.
CITATION INFORMATION: Gupta M, Levine M, Abt P. Hematopoietic Cell Transplant and Solid Organ Transplantation: A First Report of the U.S. Experience. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Gupta M, Levine M, Abt P. Hematopoietic Cell Transplant and Solid Organ Transplantation: A First Report of the U.S. Experience. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/hematopoietic-cell-transplant-and-solid-organ-transplantation-a-first-report-of-the-u-s-experience/. Accessed November 22, 2024.« Back to 2016 American Transplant Congress